NEW YORK – Omniome announced Thursday that it has raised $60 million in Series C financing, led by Madrone Capital Partners.
The San Diego-based firm said in a statement that it would use the funds to "accelerate late-stage product development and launch planning," continue optimizing its "scar-free" sequencing biochemistry, and further develop its instrument. It will also expand its workforce, especially in manufacturing, engineering, development, customer support, and commercial operations.
"The goal and vision have always been to develop a disruptive sequencing technology taking into account accuracy, speed, throughput, and cost," Omniome Executive Chairman Ken Song said in a statement. "The team's success in advancing product development across these dimensions has attracted considerable interest from top-tier investors."
The San Diego-based DNA sequencing firm has now raised at least $145 million, it said in a statement, with $60 million from its Series B financing round in 2018.